NMS · Biotechnology

TARS (TARS) Stock

$58.52 -0.73% NMS: TARS Healthcare

Valuation

MetricValue
Price$58.52
Market Cap$2.52B
P/E Ratio20.72
P/B Ratio7.41
P/S Ratio4.81
EPS (TTM)$-1.11
52-Week High$85.25
52-Week Low$38.51
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-13.96%
ROA-5.87%
ROCE-20.67%
Gross Margin79.98%
Operating Margin-3.78%
Net Margin-9.02%
Debt/Equity0.25
Current Ratio3.74

Annual Financials (USD)

Metric20212022202320242025
Revenue$57.0M$26.0M$17.0M$183.0M$451.0M
Operating Profit$-12.0M$-63.0M$-143.0M$-121.0M$-71.0M
Net Profit$-14.0M$-62.0M$-136.0M$-116.0M$-66.0M
EPS$-0.67$-2.52$-4.62$-3.07$-1.59
Op Margin-21.3%-242.9%-820.5%-65.9%-15.7%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$179.0M$228.0M$265.0M$377.0M$562.0M
Total Liabilities$12.0M$35.0M$69.0M$152.0M$219.0M
Cash$171.0M$72.0M$225.0M$95.0M$184.0M
Borrowings$2.0M$20.0M$30.0M$72.0M$94.0M

Latest News

Tarsus Pharmaceuticals (TARS) Replaces Its Commercial Chief While iRenix Talks Continue Simply Wall St. · Jul 16, 2026 RxSight Names Aziz Mottiwala as CEO MT Newswires · Jul 15, 2026 RxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer GlobeNewswire · Jul 15, 2026 Tarsus Pharmaceuticals Appoints Neera Clase as Interim Chief Commercial Officer MT Newswires · Jul 13, 2026 Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth GlobeNewswire · Jul 13, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$4.0M$-49.0M$-117.0M$-83.0M$-12.0M
Investing Cash Flow$-1.0M$-145.0M$135.0M$-201.0M$-52.0M
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$3.0M$-100.0M$153.0M$-128.0M$89.0M
Free Cash Flow$3.0M$-50.0M$-123.0M$-85.0M$-22.0M

Valuation & Return Ratios

MetricValue
PEG Ratio48.72
EV / EBITDA-46.39
FCF Yield-1.23%
Quick Ratio3.71
Interest Coverage-7.89
Return 1Y35.99%
Return 3Y133.87%
Return 5Y122.23%

Ownership

Insiders Held3.06%
Institutions Held109.84%
Institutions Float Held113.31%
Institutional HolderSharesReport Date
Deep Track Capital, Lp3,600,0002026-03-31
Blackrock Inc.3,552,6122026-03-31
RTW Investments LP3,346,0252026-03-31
Paradigm Biocapital Advisors LP2,562,1542026-03-31
Janus Henderson Group PLC2,240,9632026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPGAscentage Pharma Group International $20.18 +4.89% -9.87 $1.88B 0.00%
ADPT $24.93 +5.64% -69.84 $3.99B 0.00%
ARQT $27.84 +1.79% -158.54 $3.48B 0.00%
CELC $92.49 +5.44% -91.68 $4.51B 0.00%
CGON $72.17 -1.84% -26.72 $6.37B 0.00%

About TARS

TARS stock trades at $58.52 with a market capitalization of $2.52B. The stock is valued at a price-to-earnings (P/E) ratio of 20.72, price-to-book of 7.41, price-to-sales of 4.81. Over the past 52 weeks the stock has ranged between $38.51 and $85.25, and currently trades 31.4% below its 52-week high.

On profitability, TARS generates a return on equity (ROE) of -13.96%, return on capital employed of -20.67%, an operating margin of -3.78%, a net profit margin of -9.02%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides